Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer
Conditions
Esophageal Cancer
Conditions: official terms
Esophageal Neoplasms
Conditions: Keywords
Esophageal cancer, chemoradiation, radiosensitivity, EGFR inhibition
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: Paclitaxel Type: Drug
Name: Cisplatin Type: Drug
Name: Tarceva Type: Drug
Name: Radiotherapy Type: Radiation
Name: Radiotherapy Type: Radiation
Overall Status
Recruiting
Summary
This study is multi-center randomized phase III one to evaluate the difference in local-control and survival rate between patients receiving concurrent chemoradiotherapy combined Tarceva or not.
Detailed Description
For the esophageal carcinoma in II~III stage, routine dosage of Paclitaxel and platinum medicine chemotherapy concurrently radical radiotherapy is worthy to be studied. On this base, we advanced approach the enlarged field radiotherapy and the intervention of Tarceva. And we approach the therapeutic effect for this method theoretically, which may give a further reasonable guidance for the clinical therapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Subjects must be confirmed Esophageal Carcinoma pathologically

2. (EUS)I~IVa, without contraindication for radical radiotherapy

3. Subjects haven't been given neither radiotherapy nor chemotherapy before

4. Age 18-70,behavioral status evaluation ECOG scores 0—2 and anticipated survival more than 6 months

5. In 7 days after being selected, subjects should follow the status: WBC ≥ 4.0 x 10^9/L; ANC ≥ 1.5x 10^9/L; PLT ≥ 100 x 10^9/L; Hb ≥ 90 g/L; serum Cr ≤ ULN; serum bilirubin ≤ 1.5 ULN; ALT/AST ≤ 1.5 ULN

6. Subjects should sign for the informed consent

7. Subjects should perform good compliance

8. Male and female subjects who have the ability of fertility should take contraception during the whole course and also 3 months after last dosage.In 7 days before the inclusion, urine pregnancy tests of subjects should be negative.

Exclusion Criteria:

1. Patients who have or are currently undergoing additional chemotherapy, radiation therapy or targeted therapy

2. Complete obstruction of the esophagus, or patients who have the potential to develop perforation

3. Patients with a history of malignancy (except that skin carcinomas or in situ breast cancer, oral cancer and cervical cancer with expected survival ≥2 years

4. Patients who multiple foci esophagus

5. Patients who are/were given any other medicine tests currently/in last 4 weeks

6. Experienced hypersensitiveness with similar medicine or other kinds of bio-medicines

7. Women in status of pregnancy

8. Patients who have complications exist as following:

(1)Uncontrolled angina and heart failure, have a history of hospitalization in 3 months; (2)A history of myocardial infarction in the past 6 months; (3)There is a need for antibiotic treatment of acute bacterial or fungal infection; (4)Chronic obstructive pulmonary disease, or other lung disease requiring hospitalization; (5)Drug addiction, alcoholism and AIDS disease or long-term virus carriers; (6)Uncontrollable seizures, or loss of insight because of mental illness
Location
1st affliated hospital of Wen Zhou Medical college
Wen Zhou, Zhejiang, China
Status: Recruiting
Contact: Shixiu Wu, M.D. - +86057788069372 - wushixiu@medmail.com.cn
Start Date
May 2008
Completion Date
December 2014
Sponsors
Wenzhou Medical University
Source
Wenzhou Medical University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page